Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07472322 | ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1 | not yet recruiting | Phase 1 / Phase 2 | 31 | University of Wisconsin, MadisonOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07524530 | Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers | not yet recruiting | Phase 2 | 102 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07574541 | Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance | not yet recruiting | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07597070 | Universal Immunization to Fortify Immunotherapy Efficacy and Response(UNIFIER) | not yet recruiting | Phase 2 | 500 | University of FloridaOTHER | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07707895 | DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers | not yet recruiting | Phase 1 / Phase 2 | 60 | Boehringer IngelheimINDUSTRY | 11 | Sep 29, 2026 | clinicaltrials |
| NCT07766187 | Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma(CODAH) | not yet recruiting | Phase 2 | 12 | University of Wisconsin, MadisonOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07796373 | Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor | not yet recruiting | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07845786 | Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)(STELLAR-202) | not yet recruiting | Phase 2 | 60 | ExelixisINDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07845916 | Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer(QS-NSCLC) | not yet recruiting | Phase 2 | 12 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07846267 | Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma(CASTLE-ZS-05) | not yet recruiting | Phase 2 | 56 | Fudan UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07846358 | This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.(GFH276X1203) | not yet recruiting | Phase 1 / Phase 2 | 84 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07847671 | Fecal Microbiota Transplantation With QL1706 Plus Bevacizumab for Advanced HCC | not yet recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07847957 | Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL | not yet recruiting | Phase 1 / Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07078838 | Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer | not yet recruiting | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07698106 | Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC | not yet recruiting | Phase 1 / Phase 2 | 60 | University Health Network, TorontoOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07843940 | A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | not yet recruiting | Phase 1 / Phase 2 | 55 | Boehringer IngelheimINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT07844057 | First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma(FIRE-12) | not yet recruiting | Phase 2 | 86 | Annika KurreckOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07844551 | ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC | not yet recruiting | Phase 2 | 40 | Huashan HospitalOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07845097 | Phase II Trial Comparing Stereotactic Body Radiotherapy Versus Active Surveillance for Oligometastatic Adenoid Cystic Carcinoma | not yet recruiting | Phase 2 | 90 | All India Institute of Medical SciencesOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07419880 | Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer(RECLAIM) | not yet recruiting | Phase 2 | 46 | Fudan UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07686367 | Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers | not yet recruiting | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 0 | Sep 25, 2026 | clinicaltrials |
| NCT07709000 | A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) | not yet recruiting | Phase 2 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07840456 | Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial(InflammaSTOP) | not yet recruiting | Phase 2 | 66 | University Hospital, Basel, SwitzerlandOTHER | 2 | Sep 25, 2026 | clinicaltrials |
| NCT07841925 | A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07842198 | Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy(CARMic) | not yet recruiting | Phase 2 | 150 | Zealand University HospitalOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07842471 | Local Consolidative Therapy Versus Maintenance Immunotherapy After First-Line Chemoimmunotherapy in Metastatic NSCLC | not yet recruiting | Phase 2 | 117 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06084780 | Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)(TRANSCAPE) | not yet recruiting | Phase 2 | 20 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06836726 | Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer(EVO) | not yet recruiting | Phase 2 | 35 | University Health Network, TorontoOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07548450 | Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)(MPOWER) | not yet recruiting | Phase 2 | 25 | University of UtahOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07800507 | Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 30 | Yunnan Cancer HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07840001 | Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma(NEBULA) | not yet recruiting | Phase 2 | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07783594 | Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma | not yet recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07790913 | Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma | not yet recruiting | Phase 2 | 100 | St. Jude Children's Research HospitalOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07821112 | Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®(ENDURANCE) | not yet recruiting | Phase 2 | 20 | University of California, IrvineOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07835737 | Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 78 | West China HospitalOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT07836049 | PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC | not yet recruiting | Phase 2 | 20 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07836543 | Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer | not yet recruiting | Phase 2 | 105 | Ming ChenOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT07836712 | Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer | not yet recruiting | Phase 2 | 46 | University of Southern CaliforniaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07836777 | Efficacy and Safety of MitoQ in Improving Cancer Cachexia | not yet recruiting | Phase 2 | 20 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT07837622 | A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors | not yet recruiting | Phase 2 | 42 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05745740 | A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation | not yet recruiting | Phase 1 / Phase 2 | 26 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07265739 | Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer | not yet recruiting | Phase 2 | 27 | Massachusetts General HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07528768 | HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. | not yet recruiting | Phase 2 | 750 | The University of The West IndiesOTHER | 3 | Sep 22, 2026 | clinicaltrials |
| NCT07703436 | Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease | not yet recruiting | Phase 2 | 40 | Nuvation Bio Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07823322 | A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy(NEXERA-204) | not yet recruiting | Phase 2 | 40 | Incyte CorporationINDUSTRY | 0 | Sep 22, 2026 | clinicaltrials |
| NCT07830667 | A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat | not yet recruiting | Phase 1 / Phase 2 | 79 | Children's Oncology GroupNETWORK | 0 | Sep 22, 2026 | clinicaltrials |
| NCT07833657 | Combined Intrathecal and Systemic Therapy With Trastuzumab Rezetecan for Leptomeningeal Metastases(ITST-ADC-LM) | not yet recruiting | Phase 2 | 28 | Jiuda ZhaoOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07829926 | Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer(LENTIG-HCC) | not yet recruiting | Phase 2 | 120 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07830355 | Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph Nodes | not yet recruiting | Phase 2 | 75 | Shanghai Chest HospitalOTHER | 0 | Sep 21, 2026 | clinicaltrials |
Data updated 13 hours agoSource updated Sep 29, 2026source: clinicaltrials